JPRN-UMIN000013089招募中2 期
Maintenance Therapy of Sorafenib after Hepatic Resection for high risk recurrence hepatocellular carcinoma (MISORA) - Sorafenib after Hepatic Resection for high risk recurrence HCC (MISORA)
Department of Surgery, Kyoto University0 个研究点目标入组 35 人开始时间: 2014年2月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Previous history with sorafenib within 3 months before surgery 2. Allergy with sorafenib 3. age within the childbearing range for women 4. Severe complications 5. Patients with residual tumors 6. Other active malignancies 7. Severe renal disorders 8. Severe bronchial athma 9.severe heart disease; uncontrollable hypertension 10. Uncontrollable ascites 11. History of liver transplantaion 12. Uncontrollable esophageal varix 13. History of hepatic encephalopathy 14. Receiving medical therapy affecting sorafenib 15. Receiving herbal medicine 16. HIV-related disease 17. Patients inappropriate for study
研究者
相似试验
已完成
1 期
The effect of Sorafenib and intermittent hepatic arterial infusion chemotherapy using Cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus : a phase 1 studyAdvanced hepatocellular carcinomaJPRN-UMIN000004107Kansai Medical University Hirakata Hospital18
已完成
2 期
Randomized phase II study of sorafenib and hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma.advanced hepatocellular carcinomaJPRN-UMIN000005703ational Cancer Center Hospital105
已完成
3 期
Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCCHepatocellular CarcinomaNCT02774187Sun Yat-sen University247
已完成
不适用
Sorafenib in Hepatocellular Carcinoma Clinical Practice in ItalyHepatocellular CarcinomaNCT01539681Bayer234
Unknown
1 期
Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver CancerHepatocellular CarcinomaNCT00999843Fudan University30